These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1017 related articles for article (PubMed ID: 25543402)

  • 21. BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance.
    Adeniran AJ; Hui P; Chhieng DC; Prasad ML; Schofield K; Theoharis C
    Acta Cytol; 2011; 55(6):570-5. PubMed ID: 22156468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Morphological parameters able to predict BRAF(V600E) -mutated malignancies on thyroid fine-needle aspiration cytology: Our institutional experience.
    Rossi ED; Bizzarro T; Martini M; Capodimonti S; Fadda G; Larocca LM; Schmitt F
    Cancer Cytopathol; 2014 Dec; 122(12):883-91. PubMed ID: 25156883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of a Two-Year Routine Application of Molecular Testing of Thyroid Fine-Needle Aspirations Using a Seven-Gene Panel in a Primary Referral Setting in Germany.
    Eszlinger M; Böhme K; Ullmann M; Görke F; Siebolts U; Neumann A; Franzius C; Adam S; Molwitz T; Landvogt C; Amro B; Hach A; Feldmann B; Graf D; Wefer A; Niemann R; Bullmann C; Klaushenke G; Santen R; Tönshoff G; Ivancevic V; Kögler A; Bell E; Lorenz B; Kluge G; Hartenstein C; Ruschenburg I; Paschke R
    Thyroid; 2017 Mar; 27(3):402-411. PubMed ID: 28071986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRAF analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience.
    Pelizzo MR; Boschin IM; Barollo S; Pennelli G; Toniato A; Zambonin L; Vianello F; Piotto A; Ide EC; Pagetta C; Sorgato N; Torresan F; Girelli ME; Nacamulli D; Mantero F; Mian C
    Clin Chem Lab Med; 2011 Feb; 49(2):325-9. PubMed ID: 21175381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
    Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
    Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.
    Musholt PB; Musholt TJ; Morgenstern SC; Worm K; Sheu SY; Schmid KW
    World J Surg; 2008 May; 32(5):722-8. PubMed ID: 18235983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liquid-based cytology improves preoperative diagnostic accuracy of the tall cell variant of papillary thyroid carcinoma.
    Lee SH; Jung CK; Bae JS; Jung SL; Choi YJ; Kang CS
    Diagn Cytopathol; 2014 Jan; 42(1):11-7. PubMed ID: 23754825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutant-specific BRAF and CD117 immunocytochemistry potentially facilitate risk stratification for papillary thyroid carcinoma in fine-needle aspiration biopsy specimens.
    Meng Z; Lu J; Wu H; Zhao Y; Luo Y; Gao J; Zhu Q; Jiang Y; Li W; Liang Z
    Tumour Biol; 2016 Jan; 37(1):611-8. PubMed ID: 26240026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma.
    Givens DJ; Buchmann LO; Agarwal AM; Grimmer JF; Hunt JP
    Laryngoscope; 2014 Sep; 124(9):E389-93. PubMed ID: 24604709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of BRAF mutation detection in fine-needle aspiration biopsy samples read as "suspicious for papillary thyroid carcinoma".
    Jara SM; Bhatnagar R; Guan H; Gocke CD; Ali SZ; Tufano RP
    Head Neck; 2015 Dec; 37(12):1788-93. PubMed ID: 24989827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating BRAFV600E in the diagnosis and follow-up of differentiated papillary thyroid carcinoma.
    Pupilli C; Pinzani P; Salvianti F; Fibbi B; Rossi M; Petrone L; Perigli G; De Feo ML; Vezzosi V; Pazzagli M; Orlando C; Forti G
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3359-65. PubMed ID: 23788690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area.
    Lee ST; Kim SW; Ki CS; Jang JH; Shin JH; Oh YL; Kim JW; Chung JH
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2299-306. PubMed ID: 22500044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
    Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
    Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of false-negative papillary thyroid carcinomas by the routine analysis of BRAF(T1799A) mutation on fine-needle aspiration biopsy specimens: a prospective study of 814 thyroid FNAB patients.
    Cañadas-Garre M; Becerra-Massare P; López de la Torre-Casares M; Villar-del Moral J; Céspedes-Mas S; Vílchez-Joya R; Muros-de Fuentes T; García-Calvente C; Piédrola-Maroto G; López-Nevot MA; Montes-Ramírez R; Llamas-Elvira JM
    Ann Surg; 2012 May; 255(5):986-92. PubMed ID: 22504197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular analyses of thyroid tumors for diagnosis of malignancy on fine-needle aspiration biopsies and for prognosis of invasiveness on surgical specimens.
    Rousset B; Ziercher L; Borson-Chazot F
    Ann Endocrinol (Paris); 2011 Apr; 72(2):125-8. PubMed ID: 21511245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis.
    Park SJ; Sun JY; Hong K; Kwak JY; Kim EK; Chung WY; Choi JR
    Clin Chem Lab Med; 2013 Aug; 51(8):1673-80. PubMed ID: 23585181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
    Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA
    JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
    Zhu X; Luo Y; Bai Q; Lu Y; Lu Y; Wu L; Zhou X
    Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas.
    Kim BH; Kim IJ; Lee BJ; Lee JC; Kim IS; Kim SJ; Kim WJ; Jeon YK; Kim SS; Kim YK
    Yonsei Med J; 2015 May; 56(3):634-40. PubMed ID: 25837167
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion.
    Chakraborty A; Narkar A; Mukhopadhyaya R; Kane S; D'Cruz A; Rajan MG
    Endocr Pathol; 2012 Jun; 23(2):83-93. PubMed ID: 22105775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.